InSynchrony Ventures

InSynchrony Ventures

InSynchrony Ventures operates from Montreal, investing proprietary capital in early-stage biopharma, biotech, and therapeutic platforms. The firm is closely tied to InSymbiosis, a sister drug-development services business also founded by Dr. Dean Wenham, which gives the venture arm a built-in operational lens for scientific due diligence and post-investment support. The dual structure means portfolio companies get capital and a direct line into a contract research and development organization. The firm writes early-stage equity checks into Canadian life-science startups, concentrating on drug discovery, novel therapies, and platform biotech. Its model blends proprietary investing with hands-on industry knowledge drawn from InSymbiosis's ongoing client engagements. The geographic focus is Canada, though the firm has appeared alongside European co-investors such as High-Tech Gründerfonds in rounds like Germany-based Atriva Therapeutics. The commitment profile is direct, balance-sheet equity rather than a fund-of-funds or LP allocation. InSynchrony keeps a deliberately lean profile with no listed dedicated investment team beyond its founder and a business partner, Karl Rudolf Erlemann. Publicly tracked assets are modest — a commercial condo headquarters in Montreal and a reported sailing vessel — consistent with a principal-driven vehicle that doesn't run a large cost base. The absence of limited-partner fundraising rounds or separately managed accounts reinforces the self-funded, own-capital structure the firm describes. Structurally, the firm stands apart by operating as an investment company that shares origination tissue with a fee-for-service drug-development business. Rather than a generalist family office or a VC firm renting lab coats from a network, InSynchrony can route due-diligence signals and operational bandwidth through a permanently affiliated scientific entity — a built-in advantage for evaluating preclinical assets where the typical multi-family office lacks the necessary biology Ph.D. bench.